Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03418675 · ClinicalTrials.gov registry record · Phase 2
Brexpiprazole in Borderline Personality Disorder
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT03418675 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 80 participants.
The verdict
NCT03418675, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The primary objective of the proposed study is to evaluate the safety and efficacy of Brexpiprazole in adults with borderline personality disorder (BPD). The hypothesis to be tested is that brexpiprazole will be more effective and well tolerated in adults with BPD compared to placebo. The proposed study will provide needed data on the treatment of a disabling disorder.
Interventions
- DRUG Placebo
- DRUG Rexulti
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-11-26 |
| Est. Completion | 2021-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03418675
The ClinicalTrials.gov registry entry for NCT03418675 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03418675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03418675 about?
NCT03418675 is a clinical study titled "Brexpiprazole in Borderline Personality Disorder". The primary objective of the proposed study is to evaluate the safety and efficacy of Brexpiprazole in adults with borderline personality disorder (BPD). The hypothesis to be tested is that brexpiprazole will be more effective and well tolerated in adults with BPD compared to placebo. The proposed s...
What is the current status of trial NCT03418675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2018-11-26. Estimated completion is 2021-04-14.
What interventions are being tested in trial NCT03418675?
The interventions under investigation include: Placebo (DRUG), Rexulti (DRUG).
Who is sponsoring clinical trial NCT03418675?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.